Acetylcholinesterase inhibitor (AChEI) — dementia
Pregnancy: Not applicable (used in elderly population).
Donepezil
Brand names: Aricept
Adult dose
Dose: 5 mg once daily for 4 weeks; increase to 10 mg once daily
Route: Oral
Frequency: Once daily (at bedtime to reduce nausea/insomnia)
Max: 10 mg/day
Alzheimer's disease (mild-severe): 5 mg at night for 4 weeks, increase to 10 mg. Also used off-label in Lewy body dementia and Parkinson's dementia. NICE TA217: licensed for all stages of AD. Discontinue if no benefit at maximum tolerated dose after 3–6 months.
Paediatric dose
Route: Not applicable
Frequency: Not licensed in children
Max: Not applicable
Not licensed in children.
Dose adjustments
Renal
No dose adjustment required.
Hepatic
No dose adjustment required for mild-moderate impairment; caution in severe.
Clinical pearls
- Start at bedtime to minimise nausea — move to morning if insomnia or vivid dreams
- Anticholinergic drugs negate AChEI benefit — anticholinergic burden review essential
- Review adherence and response at 3 months; MMSE/MOCA change + carer report
- Orodispersible tablets available for patients with swallowing difficulties
- Carotid sinus hypersensitivity patients: higher syncope/bradycardia risk
Contraindications
- Hypersensitivity to donepezil or piperidine derivatives
- Sick sinus syndrome or supraventricular conduction defects
Side effects
- GI upset (nausea, diarrhoea, vomiting — most common, especially on dose increase)
- Bradycardia and syncope
- Insomnia and vivid dreams (take at bedtime or switch to morning if persistent)
- Muscle cramps
- Agitation
- Urinary incontinence
Interactions
- Anticholinergic drugs (oxybutynin, antihistamines) — antagonistic (impair cognition and reduce donepezil efficacy)
- SSRIs — additive serotonergic effects
- NSAIDs — increased GI bleeding risk
- Succinylcholine — prolonged neuromuscular blockade (AChEI effect)
Monitoring
- MMSE/MoCA (every 6 months)
- ECG (if cardiac disease or bradycardia)
- HR
- Weight
Reference: BNFc; BNF; NICE TA217 Dementia; NICE NG97 Dementia. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Mini-Mental State Examination (MMSE) · Cognitive Assessment
- MoCA — Montreal Cognitive Assessment · Cognitive Assessment
- FAST Scale for Alzheimer's Dementia · Dementia Staging
- Mini-Mental State Examination (MMSE) · Cognitive Assessment
Pathways
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5